Agalsidease-beta therapy for Fabry disease slowed progression of kidney, heart and nervous system complications and death compared to placebo, a new study found.
Data from the HALT study, Herbal Alternatives for Menopause, found that black cohosh, in three formulations, was no better than placebo in reducing symptoms of hot flashes and night sweats during menopause.
With violent crime rates reaching a 15 year record high and most prisoners testing positive for drugs, the new Congress must expand drug treatment in prisons, said Bob Weiner, former spokesman for the White House Office of National Drug Control Policy.
For injection drug users, the most productive and cost-effective approach to managing the spread of HIV is expanding syringe exchange and drug treatment, as well as promoting antiretroviral treatment for those already infected with HIV, according to a new study by researchers at Yale School of Medicine.
The latest Gamma Knife? technology is now available at Cedars-Sinai with the opening of the Gamma Knife Center at the Samuel Oschin Comprehensive Cancer Institute.
In 2003, breast cancer incidence in the United States dropped sharply, and this decline may largely be due to the fact that millions of older women stopped using hormone replacement therapy (HRT) in 2002, according to a new analysis led by researchers at The University of Texas M. D. Anderson Cancer Center.
Data was presented today showing that postmenopausal women who received ARIMIDEX (anastrozole) and Herceptin (trastuzumab) in combination had a significant improvement in progression-free survival when treated for advanced breast cancer that was both human epidermal growth factor receptor-2 (HER-2)-positive and hormone receptor-positive.
Married couples where breast cancer exists are in a risk situation when the cohesion level of the family is low, according to research carried out by the psychiatrist at the Family Diagnosis and Therapy Unit at the University Hospital of Navarra, Enrique Aub? Guedea.
Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly, according to a study conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals.
Based on results recently presented at the 2006 San Antonio Breast Cancer Symposium, researchers speculate that a sudden decrease in the incidence of breast cancer in 2003 may be due to a reduction in the use of postmenopausal hormone therapy.